172 related articles for article (PubMed ID: 9051097)
41. Significance of the signal-to-cutoff ratios of anti-hepatitis C virus enzyme immunoassays in screening of Chinese blood donors.
Ren FR; Lv QS; Zhuang H; Li JJ; Gong XY; Gao GJ; Liu CL; Wang JX; Yao FZ; Zheng YR; Zhu FM; Tiemuer MH; Bai XH; Shan H
Transfusion; 2005 Nov; 45(11):1816-22. PubMed ID: 16271110
[TBL] [Abstract][Full Text] [Related]
42. Determination of alanine aminotransferase in blood donor screening--evidence of its usefulness in the prevention of post-transfusion hepatitis.
Khouri ST; Lopes EP; Perez RM; Figueiredo VM; Lanzoni VP; Silva AE; Ferraz ML
Clin Lab; 2004; 50(5-6):291-4. PubMed ID: 15209437
[TBL] [Abstract][Full Text] [Related]
43. Prevalence of hepatitis C virus antibodies in Sydney blood donors.
Archer GT; Buring ML; Clark B; Ismay SL; Kenrick KG; Purusothaman K; Kaldor JM; Bolton WV; Wylie BR
Med J Aust; 1992 Aug; 157(4):225-7. PubMed ID: 1279363
[TBL] [Abstract][Full Text] [Related]
44. Frequency of hepatitis C viral RNA in anti-hepatitis C virus non- reactive blood donors with raised alanine aminotransferase.
Ali N; Ahmed SA; Moinuddin ; Hoch SF; Chotani RA
J Coll Physicians Surg Pak; 2011 Dec; 21(12):782-3. PubMed ID: 22166707
[TBL] [Abstract][Full Text] [Related]
45. Impact of HCV 3.0 EIA relative to HCV 2.0 EIA on blood-donor screening.
Tobler LH; Stramer SL; Lee SR; Masecar BL; Peterson JE; Davis EA; Andrews WE; Brodsky JP; Kleinman SH; Phelps BH; Busch MP
Transfusion; 2003 Oct; 43(10):1452-9. PubMed ID: 14507279
[TBL] [Abstract][Full Text] [Related]
46. Prevalence of hepatitis C virus and genotype distribution in an Australian volunteer blood donor population.
Mison LM; Young IF; O'Donoghue M; Cowley N; Thorlton N; Hyland CA
Transfusion; 1997 Jan; 37(1):73-8. PubMed ID: 9024493
[TBL] [Abstract][Full Text] [Related]
47. Evidence that use of a second-generation hepatitis C antibody assay prevents additional cases of transfusion-transmitted hepatitis.
Aoki SK; Kuramoto IK; Anderson S; Schoening V; Rodriguez R; Fernando L; Sazama K; Holland PV
J Viral Hepat; 1994; 1(1):73-7. PubMed ID: 8790562
[TBL] [Abstract][Full Text] [Related]
48. [Epidemiological information obtained from anti-hepatitis C virus screening in blood donors and candidates for autologous transfusion from 1992 to 1996 in the Alpes-Maritimes region].
Ouzan D; Pesle B; Baldini E; Rimbourg H; Darphin F; Cohen N; Brichetti A; Follana R
Gastroenterol Clin Biol; 2000 Mar; 24(3):337-41. PubMed ID: 10804343
[TBL] [Abstract][Full Text] [Related]
49. Results of HCV screening of volunteer blood donors with a chemiluminescent immunoassay and a second- or third-generation EIA: overlap of false-positive reactivity and its impact on donor management.
Kiely P; Wilson D
Transfusion; 2000 May; 40(5):580-4. PubMed ID: 10827263
[TBL] [Abstract][Full Text] [Related]
50. Prevalence of anti-HCV in Norwegian blood donors with anti-HBc or increased ALT levels.
Hetland G; Skaug K; Larsen J; Maland A; Strømme JH; Størvold G
Transfusion; 1990; 30(9):776-9. PubMed ID: 2173175
[TBL] [Abstract][Full Text] [Related]
51. Unexplained hepatitis C virus antibody seroconversion in established blood donors.
Atrah HI; Ala FA; Ahmed MM; Hutchinson F; Gough D; Baker K
Transfusion; 1996 Apr; 36(4):339-43. PubMed ID: 8623136
[TBL] [Abstract][Full Text] [Related]
52. [Serum antibodies against hepatitis C: study of 4,100 blood donors from the northeast of France].
Aymard JP; Janot C; Adjizian JC; Tamisier C; Humbert JC; Billuart M; Streiff F
Rev Fr Transfus Hemobiol; 1990 Jul; 33(4):295-302. PubMed ID: 2171543
[TBL] [Abstract][Full Text] [Related]
53. Lookback on donors who are repeatedly reactive on first-generation hepatitis C virus assays:justification and rational implementation.
Tobler LH; Tegtmeier G; Stramer SL; Quan S; Dockter J; Giachetti C; Busch MP
Transfusion; 2000 Jan; 40(1):15-24. PubMed ID: 10644807
[TBL] [Abstract][Full Text] [Related]
54. Prevalence of antibody to hepatitis C virus in a blood donor population.
Richards C; Holland P; Kuramoto K; Douville C; Randell R
Transfusion; 1991 Feb; 31(2):109-13. PubMed ID: 1847559
[TBL] [Abstract][Full Text] [Related]
55. Prevention of posttransfusion hepatitis B and C by screening for antibody to hepatitis C virus and antibody to HBcAg.
Chung HT; Lee JS; Lok AS
Hepatology; 1993 Nov; 18(5):1045-9. PubMed ID: 7693569
[TBL] [Abstract][Full Text] [Related]
56. Blood donors who are repeatedly reactive for hepatitis C virus on enzyme immunoassay and positive on recombinant immunoblot assay: evidence of failure to identify some risk factors.
Moore SB; Kruger JR; Rakela J; Vamvakas EC; Schimek C; Germer JJ; Persing DH
Transfusion; 1995 Apr; 35(4):308-12. PubMed ID: 7701548
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of antibodies to hepatitis C virus in a study of transfusion-associated hepatitis.
Esteban JI; González A; Hernández JM; Viladomiu L; Sánchez C; López-Talavera JC; Lucea D; Martin-Vega C; Vidal X; Esteban R
N Engl J Med; 1990 Oct; 323(16):1107-12. PubMed ID: 2170839
[TBL] [Abstract][Full Text] [Related]
58. Prevalence of antibody to hepatitis C virus in Pakistani thalassaemics by particle agglutination test utilizing C 200 and C 22-3 viral antigen coated particles.
Bhatti FA; Amin M; Saleem M
J Pak Med Assoc; 1995 Oct; 45(10):269-71. PubMed ID: 8714623
[TBL] [Abstract][Full Text] [Related]
59. A study of anti-hepatitis C positive blood donors: the first year of screening.
MacLennan S; Moore MC; Hewitt PE; Nicholas S; Barbara JA
Transfus Med; 1994 Jun; 4(2):125-33. PubMed ID: 7522834
[TBL] [Abstract][Full Text] [Related]
60. Prevalence of Occult Hepatitis C Virus Infection among Blood Donors in Jiangsu, China.
Lin H; Chen X; Zhu S; Mao P; Zhu S; Liu Y; Huang C; Sun J; Zhu J
Intervirology; 2016; 59(4):204-210. PubMed ID: 28208127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
